Chengdu Kanghong Pharma buys IOPtima |
|
Bio Light Israeli Life Sciences Investments Ltd., which develops various ophthalmology products, announced the completion of a deal to sell its IOPtima subsidiary on 21 November.
In April, BioLight had reported a memorandum of understanding for an initial investment in the company with an option for acquisition, and the option is now being exercised. IOPtima manufactures and markets a surgical device for treatment of glaucoma.
The acquiring company is China-based Chengdu Kanghong Pharmaceutical Group, which is listed on the Shenzhen Stock Exchange at a US$6 billion market cap. The company works in the ophthalmology field, from R&D to marketing. Please login or register to see the full article
|